| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Biotechnology (Health Care sector), GBIO's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 137.5K | $775.3K | - | |
| Other | 2.6K | $14.6K | - | |
| CFO | 1.9K | - | - | |
| 10% | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 15, 2021 | Angelino Mark D. | Chief Operating Officer | Sale+OE | 7,500 | $32.97 | $247,273.00 | -2.1% | |
| Jan 14, 2021 | Stanton Matthew91 | Chief Scientific Officer | Sale+OE | 5,630 | $32.54 | $183,212.40 | -2.8% | |
| Jan 14, 2021 | Zimmermann Tracy | Chief Development Officer | Sale+OE | 2,500 | $33.09 | $82,725.00 | -100% | |
| Jan 11, 2021 | Stanton Matthew91 | Chief Scientific Officer | Sale+OE | 14,820 | $27.69 | $410,372.19 | -7.0% | |
| Jan 11, 2021 | Kerr Douglas59 | Chief Medical Officer | Sale+OE | 11,267 | $27.58 | $310,767.87 | -3.3% | |
| Jan 11, 2021 | Rowland Charles A Jr46 | Director | Buy | 20,408 | $24.50 | $499,996.00 | +25.3% | |
| Jan 11, 2021 | Nicholson Donald William52 | Director | Buy | 4,081 | $24.50 | $99,984.50 | +4.1% | |
| Dec 15, 2020 | Angelino Mark D. | Chief Operating Officer | Sale+OE | 5,301 | $34.98 | $185,430.87 | -1.5% | |
| Dec 10, 2020 | Stanton Matthew91 | Chief Scientific Officer | Sale+OE | 10,540 | $37.62 | $396,498.94 | -5.1% | |
| Jun 16, 2020 | Flynn James E62 | 10% Owner, Possible Member Of 10% Group | Buy | 225,000 | $19.00 | $4,275,000.00 | +23.4% |